CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients

Neurol Sci. 2022 Sep;43(9):5763-5764. doi: 10.1007/s10072-022-06154-0. Epub 2022 May 26.

Authors

Francesca Schiano di Cola^{1

2}, Salvatore Caratozzolo³, Marco Bolchini³, Giulia Ceccardi³, Matteo Cortinovis³, Paolo Liberini³, Alessandro Padovani³, Renata Rao³

Affiliations

¹ Clinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy. [email protected].
² Clinical and Experimental Sciences, Università Degli Studi Di Brescia, ASST Spedali Civili Brescia, Piazzale Spedali Civili, 1, 25123, Brescia, Brescia (BS), Italy. [email protected].
³ Clinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.

No abstract available

Keywords: CGRP; Disability; Erenumab; Migraine; Prophylaxis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents, Immunological* / therapeutic use
Calcitonin Gene-Related Peptide
Calcitonin Gene-Related Peptide Receptor Antagonists / therapeutic use
Humans
Migraine Disorders* / drug therapy

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide